The entire project was carried out in a consortium with the Orphinic Scientific Bis, whose task was to commercialize the research results. The Orphinic Scientic Bis undertook to cover the costs of developing and commercializing the pharmaceutical composition - an analgesic preparation in accordance with the project's objectives in order to meet the conditions for implementation into clinical practice.
As a result of this cooperation, Trabumag was registered - the first innovative drug fully developed by Polish scientists and approved in December 2024 for use in patients by a decision of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL).
- The modified magnesium salt contained in Trabumag enhances the analgesic effect of tramadol, which allows to reduce the dose and thus reduce the risk of side effects of the opioid. It creates a very valuable therapeutic opportunity, bringing a new quality to the lives of patients with chronic pain - says Prof. Magdalena Bujalska Zadrożny.
- The registration of Trabumag is a milestone in the history of the domestic pharmaceutical industry, as it is the first original drug developed entirely in Poland. This is a great achievement for scientists and pharmacists from the Medical University of Warsaw, clinical researchers and regulatory specialists working together on this project. Reaching the commercialization stage of Trabumag is also one of the milestones in the development of our company - says Dr. Adam Kruszewski, CEO of the Orphinic Scientific SA.
The grant agreement between the National Center for Research and Development and the Medical University of Warsaw was concluded on 3.04.2013 agreement no. INNOTECH-K2/IN2/70/183154/NCBR/13 for the execution and financing of the Project implemented under the “INNOTECH” Program in the IN-TECH program pathway entitled: “Optimization of analgesic therapy - implementation of a new complex analgesic preparation”. The project was implemented in the period 1.03.2013-31.09.2017